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Role of IL-12B Promoter Polymorphism in
Adamantiades–Behcet’s Disease Susceptibility:
An Involvement of Th1 Immunoreactivity against
Streptococcus Sanguinis Antigen
Hirokatsu Yanagihori1, Noritaka Oyama1, Koichiro Nakamura1, Nobuhisa Mizuki2, Keiji Oguma3 and Fumio
Kaneko1
Adamantiades–Behcet’s disease (ABD) is a chronic inflammatory multisystem disorder. Although the precise
etiology is unclear, high prevalence of human leukocyte antigen (HLA)-B51 predisposition and predominantly
involved T-helper type 1 cells (Th1)-type proinflammatory cytokines and extrinsic Streptococcal infection
suggest a substantial association with an immunogenetic basis and strengthens the hypothesis that IL-12, a
potent inducer of Th-1 immune reaction, is a putative candidate in its pathogenesis. These clinicopathological
findings led us to examine interleukin 12 p40 (IL-12B) promoter polymorphism, for which the 4-base pair (bp)
heterozygous insertion has been shown to affect the gene transcription and subsequent protein production.
We analyzed IL-12B promoter genotypes in 194 Japanese subjects (92 with ABD and 102 normal controls) by PCR-
based restriction enzyme digestion. The frequency of the insertion heterozygosity was significantly higher in
patients than in controls (49/92, 53.3% vs 39/102, 38.2%, respectively). Comparing these with HLA haplotype data,
this trend was more significant in HLA-B51-negative patients (29/42, 69.0% vs 20/50, 40.0%; P¼ 0.005). As assessed
by semiquantitative reverse transcription-PCR and ELISA, stimulation with Streptococcal antigens specifically
increased expression of IL-12 p40 mRNA and protein, in conjunction with IL-12 p70 induction, in peripheral
blood mononuclear cells from heterozygous patients. Our results provide evidence for anti-bacterial host
response toward Th1-immunity mediated by IL-12 in patients with ABD, and the possible insight into the genetic
susceptibility that is independent of HLA background.
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INTRODUCTION
Adamantiades–Behcet’s disease (ABD) is a chronic inflam-
matory disorder characterized by oral and genital ulcerations,
various cutaneous manifestations, and ocular involvement
(McCarty et al., 2003). Owing to these widespread symptoms
overlapping medical specialities, the disease is sometimes
difficult to diagnose, although several clinical criteria are
helpful. The clinical course of mucocutaneous manifestations
may be protracted with only limited symptomatic relief from
topical ointment or anti-inflammatory agents. Systemic
immunosuppressive therapy (e.g. corticosteroid, oral cyclos-
porine, and colchicine) may be required for severe disease
with vascular, ophthalmologic, neurologic, or gastrointestinal
involvements. Thus, ABD represents morbidity and mortality,
and is also an important disease process to investigate.
Clinical and epidemiological studies have suggested that
the condition is underestimated and may have a prevalence
of more than 1 in 10,000 with almost equal sex predilection,
although this trend varies considerably in other geographic
penetration (Kurokawa et al., 2004). ABD can occur at any
age, but the highest peak ranges from adolescence to middle
age. The etiology of ABD is poorly understood, but
accumulating evidence suggests an autoimmune and genetic
basis: for example, the disease is the most common in the
Mediterranean, the Middle East, and the Far East countries,
along with the historically Silk road. In these areas, they have
reported an increased incidence of human leukocyte antigen
(HLA)-B51 in ABD patients than in healthy controls (59.4 vs
13.6%; Mizuki et al., 2001). This genetic predisposition is
irrelative with Caucasian population who lives in Western
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countries (25%; Jung et al., 1976; Chamberlain, 1977; Lehner
et al., 1982). As transgenic studies for HLA molecule are
not currently available to reproduce ABD manifestations in
mice (Takeno et al., 1995), additional hits other than HLA
restriction mechanism may be implicable as a pathogenic
importance of the disease.
From the clinical perspective, the disease activity of ABD
has been known to correlate with bacterial infection,
particularly Streptococci. The best examples for this notion
come from the fact that Streptococcus (S.) Sanguinis was
usually isolated from oral bacterial flora of the patients (Isogai
et al., 1990; Yoshikawa et al., 1991), and some patients show
a clinical improvement after tonsillectomy or administration
of antibiotics targeting Streptococci (Kaneko et al., 1997).
Moreover, skin prick test using Streptococcal antigen, but not
other common bacterial antigens, can reproduce erythema
nodosum-like eruptions and oral aphthae, those of which are
typical mucocutaneous manifestations of ABD (Kaneko et al.,
1985). A series of our recent investigation has also shown that
irrespective of HLA-restricted antigen presentation, stimula-
tion with S. Sanguinis antigen induced inflammatory cyto-
kines from peripheral blood mononuclear cells (PBMCs)
(Kaneko et al., 1997; Lee et al., 2003). Immunologically, high
titers of circulating antibody to the membrane protein
fractions (80–150 kDa) from the isolated Streptococcal strain,
a KTH-1 line, were demonstrable in part of the patients
(Yokota et al., 1995). Thus, identification of new ABD
susceptibility genes relevant to abnormal immunobiological
response against Streptococcal antigens is an important
challenge.
It has been shown that colonization with normal
commensal bacteria promotes immune tolerance and devia-
tion toward T-helper type 1 cells (Th1)-type response. IL-12 is
a Th1-type proinflammatory cytokine, which is composed of
two heterodimeric subunits, a 35-kDa chain encoded by p35
and a 40-kDa chain encoded by p40 (IL-12B). These two
subunits represent a biologically active form. IL-12 is mainly
produced by antigen-presenting cells, such as macrophages
and monocytes, and plays a crucial role in the obligatory
transformation of naı¨ve T cells into Th1 cells (Trinchieri,
1993). Several reports have documented that PBMCs from
ABD patients predominantly produce Th1 cytokines, mainly
IFN-g and tumor necrosis factor-a, and this response is more
significant in the active clinical stage, suggesting that ABD
can be categorized as a Th1-mediated disorder (Raziuddin
et al., 1998; Frassanito et al., 1999). On this basis, IL-12B
may be a potential candidate in the pathogenic importance of
ABD. Owing to its fundamentally important biological action
in the immune system, several studies have been reported so
far to link between IL-12B polymorphism and other allergic
or autoimmune disorders. Morahan et al. (2002) demon-
strated a close association between the IL-12B promoter
polymorphism and severity of children with asthma. They
revealed that heterozygosity in the IL-12B promoter sequence
reduced the gene transcription and also decreased IL-12 p70
secretion in PBMCs. Recently, a study examining the IL-12B
promoter polymorphism in skin diseases has been initiated
in psoriasis (Litjens et al., 2004), although there was no
significant association between these. The molecular-based
approaches may thus help provide some diagnostic advan-
tages in the confusing clinical characteristics of ABD (i.e.
mimicking disease such as Crohn’s disease or symptoms
that do not fulfill the clinical criteria of ABD), and more
specifically understanding as yet unidentified immunopatho-
genesis of the disease, particularly Th1-predominant immu-
nity and aberrant reactivity to Streptococcus antigens. In this
study, therefore, we screened the same IL-12B promoter
polymorphism in a large cohort of ABD to test the hypothesis
that such a genetic background would affect abnormal
immune response against Streptococcal antigen mediated
by IL-12 production, and to correlate these with the
immunopathogenic consensus so far reported in ABD.
RESULTS
Frequency of IL-12B promoter polymorphism
We initially determined HLA-B genotypes in all patients and
comparative normal control subjects. The results showed a
significantly higher incidence of HLA-B51 in ABD patients
than in controls (50/92, 54.3% vs 13/102, 12.7%; Po0.001),
as were similar to the previous report (Yanagihori et al.,
2004).
Next, we examined a 4-base pair (bp) insertion poly-
morphism within IL-12B promoter region in the same cohort
by a PCR-based restriction enzyme digestion. This assay
allowed detection of two distinct bands, 79-bp, the common
product, and either 206-bp (inserted allele) or 202-bp (non-
inserted allele; Figure 1). Overall, the genotypic analysis
revealed that our cohort has heterozygous (þ /) or homo-
zygous states (/ or þ /þ ) of IL-12B promoter polymorph-
ism. The frequencies of these allelic variations comprised
32.6% (/), 53.3% (þ /), and 14.1% (þ /þ ) in ABD
patients, whereas there were 43.1% (/), 38.2% (þ /),
and 18.6% (þ /þ ) in normal controls. The distribution of the
IL-12B promoter genotypes did not deviate from the expected
Hardy–Weinberg equilibrium. Although we found no differ-
ences in IL-12B promoter genotypes between these two
groups (w2 test, P¼ 0.145), there were statistically significant
differences between heterozygosity (53.3%) and homozyg-
osity (46.7%) in ABD as compared to those in normal
controls (38.2 and 61.8%, respectively; P¼0.036; Table 1).
Upon combining with the data of HLA-B51 genotypes in
ABD patients, the HLA-B51-negative patients had a signifi-
cantly higher incidence of IL-12B promoter heterozygosity in
comparison with HLA-B51-positive patients (29/42, 69.0% vs
20/50, 40.0%, respectively; P¼ 0.005; Table 2).
206 bp
202 bp
+/+–/–+/–M
Figure 1. Detection of IL-12B promoter polymorphism. The PCR products
from amplification using IL-12B promoter-specific primers were electro-
phoresed on 4% high-resolution agarose gels and visualized with ethidium
bromide staining. The insert and non-inserted alleles were designated ‘‘þ ’’
and ‘‘’’, respectively; three different allelic variations for IL-12B promoter,
homozygous (/ and þ /þ ) and heterozygous (þ /), are indicated. M,
20-bp molecular weight markers.
www.jidonline.org 1535
H Yanagihori et al.
IL-12B Promoter Polymorphism in Behcet’s Disease
Production of IL-12 p40/p70 subunits
To address in vitro/in vivo abnormal reactivity against
Streptococcal antigens in ABD patients (Kaneko et al.,
1997, 2003), we determined IL-12 p40 and p70 production
levels in response to KTH-1 (uncommon serotype 1, strain
113-20) S. Sanguinis antigen and lipopolysaccharide (LPS;
Figure 2). For this assay, our cohort (n¼ 194) was classified
into four different subgroups by means of genotypic variations
of IL-12B promoter polymorphism: homozygous disease
(n¼43) and normal (n¼63), and heterozygous disease
(n¼49) and normal (n¼39). As assessed by IL-12 subunit-
specific ELISA, our time-course experiment revealed that the
steady-state level of IL-12 p40 production from PBMCs in
ABD patients did not differ from that in normal (data not
shown). By stimulation with 1mg/ml S. Sanguinis antigen,
however, we found approximately 2–2.5-fold increase of IL-
12 p40 production from PBMCs in ABD patients with IL-12B
promoter heterozygosity when compared to other three
subgroups (repeated measure analysis of variance (ANOVA),
P¼0.0011; post hoc test, Po0.05). The response was evident
at day 1 after the stimulation and reached a plateau up to day
7 culture. Stimulation with LPS showed a similar trend in all
four subgroups, although we failed to obtain a statistical
significance other than at day 5 culture.
Looking at the production levels of IL-12 p70, there was a
tiny but similar response seen in IL-12 p40 induction
(Figure 3). By stimulation with S. Sanguinis antigen, we
found approximately 2–4-fold increase of IL-12 p70 produc-
tion from PBMCs in ABD patients with IL-12B promoter
heterozygosity, but did not in other three subgroups (repeated
measure ANOVA, P¼0.0001; post hoc test, Po0.05).
Interestingly, the mean level of S. Sanguinis-induced IL-12
p70 decreased in a time-dependent manner, suggesting the
feedback autoregulation in IL-12 p70 production. In contrast,
stimulation with LPS did not provide any significant results in
IL-12 p70 production among all four subgroups, further
implicating the IL-12 subunit-dependent induction by Strep-
tococcal antigen. These results suggest that the IL-12B
promoter heterozygosity specifically affects its gene tran-
scription and protein production of IL-12 p40/p70 subunits
from patients’ PBMCs in response to S. Sanguinis antigen, and
Table 1. IL-12B promoter genotypes in ABD patients and normal controls
Genotype of IL-12B promoter ABD (n=92) Control (n=102) v2 P OR (95% CI)
Homozygous (genotype +/+ or /) 43 (46.7%) 63 (61.8%) 4.4 0.036 1.8 (1.0–3.3)
Heterozygous (genotype +/) 49 (53.3%) 39 (38.2%)
OR, odd ratio; CI, confidence intervals.
Table 2. Frequencies of IL-12B promoter genotypes in HLA-B51-positive and -negative patients
ABD HLA-B51
Genotype of IL-12B promoter Positive (n=50) Negative (n=42) v2 P OR (95% CI)
Homozygous (genotype +/+ or /) 30 (60.0%) 13 (31.0%) 7.7 0.005 3.3 (1.4–7.9)
Heterozygous (genotype +/) 20 (40.0%) 29 (69.0%)
OR, odd ratio; CI, confidence intervals.
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Figure 2. IL-12 p40 production from LPS- and S. Sanguinis
antigen-stimulated PBMCs. After PBMCs were stimulated with 0.1 ng/ml
LPS (a) and 1 mg/ml KTH-1 S. Sanguinis antigen (b) for the indicated periods
(day 1, 5, and 7), the culture supernatants were analyzed with IL-12
p40-specific ELISA. The cells were taken from four different subgroups in
terms of IL-12B promoter genotypes; normal control with heterozygosity
(white columns) and homozygosity (crosshatched columns), and ABD
patients with heterozygosity (black columns) and homozygosity (gray
columns). Repeated measure ANOVA was used to compare the IL-12
p40 production levels between S. Sanguinis antigen-stimulated PBMCs
(P¼0.0011) and LPS-stimulated PBMCs (P¼ 0.0518), whereas post hoc test
to compare between four subgroups. Asterisks indicate the statistical
significance with post hoc tests lower than Po0.05.
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that this response is in part mediated by antigen-specific
regulation.
Expression of IL-12 p40 mRNA in PBMCs stimulated by S.
Sanguinis antigen
We examined the levels of IL-12 p40 mRNA (Figure 4). In
PBMCs from all four IL-12B genotypes, the steady-state levels
of IL-12 p40 mRNA were not detectable even at day 5
culture, whereas we found the marked expression by
stimulation with S. Sanguinis antigen. This induction was
most prominent in PBMCs from ABD patients with IL-12B
promoter heterozygosity as compared to other three sub-
groups. There was a similar response in LPS-stimulated
PBMCs, with lesser induction levels of IL-12 p40 mRNA (data
not shown).
DISCUSSION
In this study, we have elucidated the characteristic gene
polymorphisms of the proinflammatory cytokine that is
possibly relevant to the immunopathogenic importance of
ABD. Our genotyping study using a large cohort (n¼194)
showed that heterozygosity for the 4-bp insertion polymorph-
ism within IL-12B promoter region contributes to the suscepti-
bility of ABD. More specifically, this allelic variation is closely
associated with increased production of IL-12 p40/p70 in
PBMCs from ABD patients in response to the common
bacterial antigens. The most pronounced reaction was
obtained in the patients’ PBMCs upon stimulation with KTH-
1 S. Sanguinis antigen. These results indicate the involvement
of differential immune response against environmental micro-
organisms in ABD. This observation extends our previous
findings demonstrating that oral bacterial flora of ABD patients
consists of Streptococci (Kaneko et al., 1985; Yokota et al.,
1995), and that Bes-1 (encoding KTH-1 S. Sanguinis antigen
correlated with ABD) DNA fragment can be detected in
erythema nodosum-like eruption and oral aphthous lesions in
ABD (Tojo et al., 2003). This combined evidence may thus
help illustrate the extrinsically pathogenic relevance of
Streptococcal antigens mediated by IL-12 in ABD.
Interestingly, the IL-12B promoter polymorphism was
mostly found in HLA-B51-negative patients. Given the fact
that Japanese ABD patients have considerably higher
prevalence of HLA-B51 than that of other West European
countries (Jung et al., 1976; Chamberlain, 1977; Lehner et al.,
1982), it is possible that the IL-12B promoter heterozygosity is
not associated with HLA predisposition. This is in agreement
with the recent reports suggesting the involvement of HLA-
dependent and -independent genes in susceptibility of ABD
(Boiardi et al., 2001; Salvarani et al., 2002, 2004).
The IL-12B promoter polymorphism has recently been
shown to affect the gene transcription, although the precise
molecular mechanism is unknown. The heterozygous state
was associated with disease severity of child patients with
atopic/non-atopic asthma, as was mediated by decreased
production of IL-12 mRNA and protein in PBMCs upon
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Figure 3. IL-12 p70 production from LPS- and S. Sanguinis
antigen-stimulated PBMCs. After PBMCs stimulated with 0.1 ng/ml LPS
(a) and 1 mg/ml KTH-1 S. Sanguinis antigen (b) for the indicated periods (day
1, 5, and 7), the culture supernatants were analyzed with IL-12 p70-specific
ELISA. The cells were taken from four different subgroups in terms of IL-12B
promoter genotypes; normal control with heterozygosity (white columns)
and homozygosity (crosshatched columns), and ABD patients with
heterozygosity (black columns) and homozygosity (gray columns).
Repeated measure ANOVA was used to compare the IL-12 p70
production levels between S. Sanguinis antigen-stimulated PBMCs
(P¼0.0001) and LPS-stimulated PBMCs (P¼ 0.913), whereas post hoc test to
compare between four subgroups. Asterisks indicate the statistical
significance with post hoc tests lower than Po0.05.
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Figure 4. Semi-quantitative reverse transcription-PCR analysis of IL-12 p40
mRNA expression. Expression levels of IL-12 p40 mRNA in
S. Sanguinis-stimulated PBMCs at day 0 and day 5 were determined by
semiquantitative reverse transcription-PCR. For normalization of the mRNA
expression levels, b-actin mRNA was used as an internal control. A
representative of three independent experiments is shown (a). The results
are expressed as the ratios of optical densities (OD) to b-actin bands, and
represent the mean value7SD of three experiments (b); normal control with
heterozygosity (white columns) and homozygosity (crosshatched columns),
and ABD patients with heterozygosity (black columns) and homozygosity
(gray columns).
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stimulation with LPS and IFN-g (Morahan et al., 2002). As
assessed by reverse transcription-PCR and ELISA, however,
we found the opposite responses; stimulation with
S. Sanguinis antigen or LPS induced IL-12 p40 gene
transcription and protein production, as well as increased
IL-12 p70 production, in patients’ PBMCs with IL-12B
promoter heterozygosity. The increased IL-12 levels contin-
ued for up to 7 days. Nevertheless, there was a concomitant
decrease of the mean levels in IL-12 p70 production. Thus, it
is likely that IL-12B promoter heterozygosity contributes to
not only ABD susceptibility but also loss of feedback
inhibition of the IL-12 p40 gene expression.
Genome-wide linkage analysis for ABD has well been
documented in many ethnic groups. Among these, the most
disease-susceptible genes include HLA-B51 and major
histocompatibility complex class I chain-related gene A,
locating a 46-kilobase centromeric portion to the HLA-B
gene (Ota et al., 1999). While comparing between ethnically
matched populations, ABD patients tend to have a high
prevalence of a triplet repeat polymorphism within the
transmembrane region of major histocompatibility complex
class I chain-related gene A gene (Mizuki et al., 1997). Both
of these genes are clustered on chromosome 6. Contrary to
this genetic implication, IL-12 p40 gene locates on chromo-
some 5q31.1–q33.1, and thus far, there are no available data
for linkage equilibrium with chromosome 5 or even the
region that is at close proximity to this locus in ABD.
Moreover, our recent investigation demonstrated less asso-
ciation between 1188A/C single-nucleotide polymorphism
within 30-untranslated region of IL-12B, which is highly
detected in autoimmune-based diseases, and ABD suscept-
ibility. The discrepant results between the genome-wide
microsatellite mapping and individual gene polymorphisms
are in accordance with other chronic inflammatory and
allergic disorders, that is, psoriasis, asthma, and atopic
dermatitis (Tsunemi et al., 2002; Randolph et al., 2004).
Despite their highly inherited condition, these diseases have
been considered to be associated pathogenically with a
variety of extrinsic and intrinsic factors, such as bacterial and
viral infections, and stress (Gul, 2001; Kaneko et al., 2003). It
may therefore not be surprising that epidemiological and
genetic approaches to address the miscellaneous clinical
presentation of ABD have imperfectly covered important
areas of its pathogenesis. Another explanation for the
discrepancy would include differences in the genetic back-
grounds between the investigated populations, as well as
differences in the design and setting of the study. Therefore,
investigations regarding a large cohort multicenter study for
analyzing the qualification of disease-susceptible genes and
identification of symptom-specific gene polymorphisms are
needed to understand the immunogenetic nature of ABD.
A further intriguing finding in our study is that the IL-12B
promoter heterozygosity accounts for the overproduction of
IL-12 p40/p70 in response to antigenic microorganisms.
Apart from epigenetic DNA modification (i.e. methylation or
acetylation), there are no proper explanations for ‘‘hetero-
zygote sufficiency’’ at the gene expression. Hypothetically,
these disease-susceptible polymorphisms would be in linkage
equilibrium with each of the promoter alleles, and would
rather appear in patients with homozygosity. For this
phenomenon, one may speculate that the heterozygous
allele potentially carries impaired stability of the gene
transcription. Once upon stimulation with antigenic micro-
bial organisms – especially Streptococcal antigens – intensity
of signal transductions and/or induction rates for unstabilized
IL-12 p40 gene expression may be abruptly overdriven in
immune cells. Besides, it should be noted that normal control
subjects with IL-12B heterozygosity did not show such anti-
bacterial immune responses. As Streptococcal antigens and
LPS are originated constitutively from the common bacterial
flora in human, the development of ABD manifestations
may need further additional background, for example,
more characteristic predisposition of HLA-B51 genotypes
(B*5101–5121) or other inflammation-mediated gene
polymorphisms, notwithstanding that a number of molecular
studies for discovering such candidate genes in ABD
susceptibility have not yet provided the novel genetic
implication other than HLA and major histocompatibility
complex class I chain-related gene A genes (Mizuki et al.,
1992; Yanagihori et al., 2004). As the magnitude of these
associations may differ among the individual genes, we need
to ascertain whether these disease-related genes may act
independently or together with, or even just simply modify
the clinical course of the disease. It is therefore conceivable
that a certain combination of several genes responsible
for ABD pathophysiology confers imbalance of anti-bacterial
host defence, and eventually elicit abnormal immune
response against antigenic microorganisms, particularly
Streptococcus antigens. The chronicity of these subsequent
reactions may cause the constitutive shift to Th-1 autoimmu-
nity, thereby contributing to the development of ABD
symptoms and/or exacerbation of the disease.
In view of the clinical perspective, our experimental data
strongly support the previous observation that anti-bacterial
agents targeting Streptococcus (i.e. tetracycline or macroride)
aid the resolution of mucocutaneous symptoms of ABD
(Kaneko et al., 1997). Taken together, Mannon et al. (2004)
have shown that administration of IL-12-specific monoclonal
antibody was indeed effective for the treatment of Crohn’s
disease, which is often difficult to discriminate clinically
from ABD. In a mouse model for Crohn’s disease, injection
of anti-IL-12 antibody can prevent the systemic inflammatory
condition (Neurath et al., 1995), implicating molecular basis
of the new therapeutic application targeting IL-12 in ABD.
Considering these therapeutic advancement, we propose that
it is noteworthy to address the IL-12B promoter genotypes in
individual ABD patients.
In conclusion, our data highlight the possible association
between the 4-bp insertion polymorphism within IL-12B
promoter and susceptibility of ABD in Japanese patients. The
allelic heterozygosity can be responsible for abnormal IL-12
p40/p70 production against Streptococcal antigens. Our data
are the first documentation for the underlying immunopatho-
genesis relevant to the predominant Th-1 immune response
induced by IL-12 in ABD. Given the lack of published criteria
for determining the clinical severity of ABD and a consider-
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ably variety of medical management (i.e. various specialized
consultations and treatments), our present study did not allow
comparisons between the clinical presentation and respon-
siveness to the ongoing treatment and IL-12B promoter
genotypes. Further investigations for linking these individual
clinical aspects now need to be opened.
MATERIALS AND METHODS
Subjects
Participants were part of an ongoing study in a large community-
based cohort organized by Ministry of Health, Labour and Welfare in
Japan. In detail, 92 Japanese patients with ABD (52 males and 40
females, mean age 49.5718.3 years, range 21–77 years) were
recruited from the Department of Dermatology, Fukushima Medical
University Hospital (Fukushima, Japan) and the Department of
Ophthalmology, Yokohama City University Hospital (Yokohama,
Japan). All patients were diagnosed on the basis of the clinical
criteria proposed by the International Study Group for Behcet’s
disease by at least two dermatologic and ophthalmologic specialists.
They had no clinical overlap with other systemic inflammatory
diseases or autoimmune disease. Of these ABD patients, 55 DNA
samples had been shown previously to have no association with
1188A/C single-nucleotide polymorphism in IL-12B 30-untranslated
region (Yanagihori et al., 2004). All clinical information was
accurately recorded at the same time as blood samples were taken.
As a control, 102 healthy Japanese volunteers (54 males and 48
females, mean age 28.077.8 years, range 19–62 years) with no
history of autoimmune and allergic diseases were randomly chosen
from our archival DNA samples. This study was conducted
according to the Declaration of Helsinki Principles. The local ethical
committees approved the design of our study. All subjects enrolled
in this study gave their informed consent.
HLA genotyping and detection of IL-12B promoter polymorph-
ism
Genomic DNA was obtained from whole peripheral blood cells by
using a standard proteinase K digestion and subsequent phenol/
chloroform extraction (Yanagihori et al., 2004). The DNA samples
were extracted just before the polymorphism detection procedure.
HLA-B genotype was determined by a PCR-based sequencing as
described previously (Yanagihori et al., 2004).
For detection of the 4-bp insertion polymorphism within IL-12B
promoter (GenBank AC011418), PCR was performed for DNA
amplification. On the basis of the previously published data
(Morahan et al., 2002), the primers used were designed specifically
for IL-12B promoter: forward, 50-TCAGACACATTAACCTTGCA-30;
reverse, 50-AGGTTCTAATGTGGTCATTG-30.
The amplification conditions were 941C for 5 minutes, followed
by 35 cycles of 941C for 30 seconds, annealing temperature 561C for
30 seconds, and 721C for 30 seconds with a final extension for
10 minutes at 721C. The reaction mixture contains 5 ng of individual
genomic DNA as a template, 20 pmol of the primers, 2.5 mM MgCl2,
1 mM dNTPs, and 1 U of Taq DNA polymerase (TaKaRa Bio Inc.,
Tokyo, Japan). To analyze the 4-bp insertion polymorphism, aliquots
of PCR products (10 ml in each) were digested with 0.5 U HindIII
(TaKaRa Bio Inc.) for at least 1 hour at 371C, and were subsequently
electrophoresed on 4% high-resolution agarose gel (Agarose-1000;
Invitrogen Co., Carlsbad, CA) containing ethidium bromide to
visualize two distinct bands (Figure 1). To exclude the possibility
of introducing PCR error and miscutting of the restriction enzyme, all
steps were repeated at least twice. When we encountered
unconvincing results in the above experiments, the PCR products
were sequenced directly with an automated DNA sequencer
CEQ2000XL (Beckman Coulter, Fullerton, CA).
Cell culture
PBMCs were taken from ABD patients (n¼ 8), in whom systemic
corticosteroids and immunosuppressants have not yet been given,
and age-matched normal healthy volunteers (n¼ 9). The cells were
isolated from heparinized peripheral blood with a Ficoll Paque
density-gradient centrifugation (Lymphoprep, Axis-Shield PoC AS,
Oslo, Norway). The PBMCs obtained were adjusted to 5.0 105
cells/ml in an endotoxin-free RPMI 1640 medium (Invitrogen)
supplemented with 10% heat-inactivated fetal calf serum in a 24-
well plate, and were then cultured with indicated doses of LPS
(Sigma, St. Louis, MO), S. Sanguinis antigen from a KTH-1 line
(kindly provided by Dr Oguma K, Okayama University, Okayama,
Japan), or a medium alone for up to 7 days in a 5% CO2-humidified
incubator. After stimulation, the culture supernatant and cells were
corrected at day 1, day 5, and day 7, and then stored at 701C until
the following assay. Optimal doses of the stimulants for cytokine
production were determined in pilot experiments. The tested doses
of LPS and S. Sanguinis antigen ranged from 0.1 to 10 and 100 to
1000 ng/ml, respectively.
IL-12 ELISA
To determine IL-12 p40 and p70 protein production in the culture
supernatant, we performed ELISA with commercially available kits
(IL-12 p40; R&D systems Inc., Minneapolis, MN; IL-12 p70,
Biosource Europe SA, Fleurus, Belgium), following the manufac-
turer’s instructions. The sensitive limits for quantitative determina-
tions of IL-12 p40 and p70 were 15 and 0.5 pg/ml, respectively. Each
sample was assayed in duplicate.
RNA extraction and semiquantitative reverse transcription-PCR
According to the previous study (Akiba et al., 2002), total RNA was
extracted from the PBMCs by using Isogen reagent (Nippon gene,
Tokyo, Japan). Aliquots of DNase I (TaKaRa Bio Inc.)-treated total
RNA (1mg/reaction) was reverse transcribed with random primers
(TaKaRa Bio Inc.) and Superscript II reverse transcriptase (Invitro-
gen). The final amount of RNA in each reaction was normalized
using the amount of housekeeping gene b-actin mRNA. The cDNA
obtained was amplified by PCR step using different sets of primers:
for b-actin as an internal control,
forward, 50-GACTATGACTTAGTTGCGTTA-30,
reverse, 50-GCCTTCATACATCTCAAGTTG-30,
for IL-12B,
forward, 50-TGGCCAGTACACCTGTCACAAAG-30,
reverse, 50-CAGCAGGTGAAACGTCCAGAATAA-30.
The amplification conditions were optimized by different settings
of PCR, and finally conducted with 35 cycles consisting 30 seconds
at 941C, 30 seconds at 621C, and 30 seconds at 721C. The PCR
products were electrophoresed on 1.5% agarose gel and were then
visualized by ethidium bromide staining. Intensity of each band was
analyzed by a Luminous Imager densitometer (Aisin Seiki Co., Ltd,
Aichi, Japan), and were expressed as the ratio of optical densities to
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b-actin bands (Figure 4). The results were representative of three
independent experiments.
Statistical analysis
Statistical significance (Po0.05) was determined using StatView
version 6 for Windows (SAS Institute Inc., Cary, NC). The distribution
of the IL-12B promoter genotypes was compared using w2 test.
Repeated measure ANOVA and post hoc tests were used to assess
levels of IL-12 p40 and p70 production.
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